Dr Thielmann has a PhD in Physical Chemistry/ Material Science from the University of Duesseldorf, Germany. Frank joined Novartis Pharmaceutical Development (Basel, Switzerland) in July 2007 as Formulation Lab Head. From August 2009 until February 2011 he managed the pharmaceutical development group at the Horsham site, UK. Upon his return to Basel he took on the responsibility for the local formulation technology platform until February 2012.

Subsequently he joined Novartis Technical Operations where he was managing the setup of a new solid dosage form manufacturing facility and the transfer of the corresponding portfolio before moving to the Biotechnology department as global Leader for PMO & Operational Excellence in November 2016, In this role Frank had an additional responsibility as Operational Excellence Head of the new Novartis manufacturing facility for Cell & Gene Therapeutics in Switzerland.

In November 2019, Dr Thielmann moved to a new responsibility at Takeda Manufacturing & Supply as Operational Excellence Director, where he is responsible for the implementation of process improvement in the manufacturing of a wide portfolio ranging from small molecules to ATMPs.

Dr Thielmann is member of the Steering Committee of the Material Science and Biotherapeutics Focus Group in the British Academy of Pharmaceutical Sciences.

 

What is the pop in your job? "Being able to influence strategic decisions"

What drives you? "Making better and affordable medicines for our patients"

What is your passion? "Combining science with business"

 

For more than 230 years, Takeda has brought hope to people around the world through our people-centered and innovation-driven approach to science and medicine. As a global pharmaceutical leader, we focus on solving unmet needs where we can make a real difference—and on putting patients first. Our therapeutics focus is oncology, gastroenterology, and the central nervous system, as well as vaccines.